Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

EMA Validates Application for Liso-Cel in Relapsed/Refractory Follicular Lymphoma

August 19th 2024

The EMA has expanded the indication for lisocabtagene maraleucel to include the treatment of patients with relapsed or refractory follicular lymphoma.

Tafasitamab Plus R2 Improves PFS in Relapsed/Refractory Follicular Lymphoma

August 16th 2024

Tafasitamab plus lenalidomide and rituximab improved progression-free survival vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Targeted Therapy Combinations Could Represent Next Wave of Treatments in Follicular Lymphoma

August 15th 2024

Geoffrey Shouse, DO, PhD, discusses the benefits of utilizing targeted therapy approaches in the treatment of patients with follicular lymphoma.

Dr Shouse on Currently Available Targeted Therapies for FL

August 13th 2024

Geoffrey Shouse, DO, PhD, discusses currently available targeted therapies for the management of follicular lymphoma.

Wearable-Captured Metrics and ePROs Prove Feasible as Digital Ecosystem in Waldenström Macroglobulinemia

August 12th 2024

Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.

FDA Approves Denileukin Diftitox for R/R Cutaneous T-Cell Lymphoma

August 8th 2024

The FDA has approved denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

EMA Grants Orphan Drug Designation to SLS009 for R/R PTCL

August 6th 2024

The European Medicines Agency has granted orphan drug designation to SLS009 for relapsed/refractory peripheral T-cell lymphoma

Outpatient Treatment With Subcutaneous Epcoritamab Shows Feasibility in R/R DLBCL and Follicular Lymphoma

August 5th 2024

Subcutaneous epcoritamab demonstrated safety when given in the outpatient setting in relapsed/refractory diffuse large B-cell and follicular lymphoma.

Epcoritamab Optimization Lowers Neurotoxicity, Boosts Outpatient Feasibility in Follicular Lymphoma

August 5th 2024

Julie M. Vose, MD, MBA, discusses results with epcoritamab from the follicular lymphoma cycle 1 optimization cohort of the phase 1/2 EPCORE NHL-1 trial.

Alemtuzumab Earns FDA Orphan Drug Designation for Lymphodepletion Before UCART22 in R/R B-ALL

August 2nd 2024

Alemtuzumab was FDA granted orphan drug designation as part of lymphodepletion prior to UCART22 in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr Wang on Research With Menin Inhibitors in AML/ALL

August 2nd 2024

Eunice Wang, MD, discusses ongoing research with menin inhibitors in patients with acute leukemias, as presented at the 2024 EHA Congress.

FDA Grants Fast Track Designation to Soquelitinib for Relapsed/Refractory PTCL

August 1st 2024

Soquelitinib has received fast track designation from the FDA for patients with relapsed or refractory peripheral T-cell lymphoma after at least 2 lines of systemic therapy.

Precision Epigenetic Targeting for Germinal Cancer Lymphomas

July 29th 2024

Jennifer Effie Amengual, MD, of Columbia University Hebert Irving Comprehensive Cancer Center, discusses precision epigenetic targeting for germinal cancer lymphomas.

Reduced Incidence of ICANS and CRS After 2 Weeks Post-CAR T Supports Shortened Monitoring Period in DLBCL

July 24th 2024

The incidence of ICANS and CRS post-CAR T-cell therapy decreased after 2 weeks in patients with DLBCL, supporting a reduction of the monitoring period.

Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma

July 17th 2024

Odronextamab elicited deep, durable responses in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups

July 17th 2024

Brentuximab vedotin plus lenalidomide/rituximab (R2) provided a superior overall survival benefit vs R2 alone in relapsed/refractory DLBCL.

Dr Nowakowski on the FDA Approval of Epcoritamab in R/R Follicular Lymphoma

July 17th 2024

Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

Oral Bexarotene Gains Marketing Authorization for CTCL in Hong Kong

July 16th 2024

Bexarotene has been granted marketing authorization in Hong Kong for the treatment of pretreated cutaneous manifestations of cutaneous T-cell lymphoma.

CAR T-Cell Therapy Selection in Follicular Lymphoma Requires Careful Consideration

July 15th 2024

Francisco Hernandez-Ilizaliturri, MD, details factors that influence CAR T-cell therapy selection in relapsed/refractory follicular lymphoma.

Epcoritamab Shines in Third-Line Follicular Lymphoma With the Potential to Move into Earlier Lines

July 12th 2024

Grzegorz S. Nowakowski, MD, discusses the accelerated approval of epcoritamab in follicular lymphoma, touching on key trial data and remaining unmet needs.